Clinical oncology : a journal of the Royal College of Radiologists
-
Clin Oncol (R Coll Radiol) · May 2006
Prediction of urinary symptoms after 125iodine prostate brachytherapy.
To evaluate the post-treatment urinary morbidity experienced by a cohort of men undergoing ultrasound-based transperineal prostate brachytherapy, as monotherapy for early stage carcinoma of the prostate. ⋯ Brachytherapy was generally well tolerated, with urinary toxicity in most patients persisting for at least 3-6 months after prostate brachytherapy. Those whose pre-treatment prostate volume and IPSS were high experienced more severe urinary symptoms in the first few months.